Evidence map›Paper›PMID 42877110›Full record

ReviewFrontiers in immunology2026

Gut microbiota in genetic diseases: from Mendelian disorders to complex traits.

Guanjun Chen, Junrong Li, Tianjun Huang, Dan Zeng, Limin Mo, Jun Li, Chunjiang Zhu

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guanjun Chen *The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Junrong Li *The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Tianjun Huang *The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Dan ZengThe First Affiliated Hospital of Guilin Medical University, Guilin, China.
Limin MoThe First Affiliated Hospital of Guilin Medical University, Guilin, China.
Jun LiThe First Affiliated Hospital of Guilin Medical University, Guilin, China.
Chunjiang ZhuThe First Affiliated Hospital of Guilin Medical University, Guilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a core component of the human microecosystem, the dynamic balance of the composition and function of gut microbiota is essential to host health. In recent years, numerous studies have demonstrated that gut dysbiosis is not only associated with metabolic diseases and immune disorders but also plays a pivotal role in the pathogenesis of hereditary diseases. Ranging from chromosomal diseases (e.g., Down syndrome), monogenic diseases (e.g., cystic fibrosis, phenylketonuria, familial adenomatous polyposis, hereditary hemolytic anemia), mitochondrial diseases (e.g., Leber's hereditary optic neuropathy, mitochondrial encephalomyopathy) to polygenic hereditary diseases (e.g., inflammatory bowel disease, autism spectrum disorder, obesity and diabetes), gut microbiota can markedly alter the manifestation and severity of disease phenotypes by regulating host immune responses, metabolic pathways and gene expression. Nevertheless, the bidirectional interaction network between host genes and gut microbiota has not been fully elucidated. Most existing studies merely focus on correlation analysis, and in-depth exploration of causal mechanisms remains insufficient. This review elaborates on the mechanisms of gut microbiota in monogenic diseases and hereditary diseases with complex phenotypes. By integrating the latest advances in genomics, metabolomics and microbiomics, it discusses how gut dysbiosis affects disease progression via immune modulation, metabolite reprogramming and epigenetic modification. Meanwhile, this paper summarizes the current status and challenges of clinical translation of microbiota-targeted therapies, such as probiotics and fecal microbiota transplantation(FMT), in the treatment of hereditary diseases. This review aims to provide a microecological perspective for understanding the pathogenesis of hereditary diseases and offer theoretical support for personalized and precise intervention.

Indexed as

DysbiosisGastrointestinal MicrobiomeGenetic Diseases, InbornAnimalsHumansPhenotypegut dysbiosisgut microbiotahereditary diseaseshost-microbiota interactionprecision medicine

Identifiers

PMID42877110
PMCPMC13662852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.